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Abstract: Varenicline is a new prescription stop smoking medication (SSM) that has been 
available in the United States since August 1, 2006, in the United Kingdom and other 
European Union countries since December 5, 2006, in Canada since April 12, 2007, and in 
Australia  since  January  1,  2008.  There  are  few  population-based  studies  that  have 
examined use rates of varenicline and other stop smoking medications. We report data 
from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and 
Australia  who  reported  an  attempt  to  quit  smoking  in  past  year  in  the  2006  
survey  (n  =  4,022  participants),  2007  (n  =  3,790  participants),  and  2008  surveys  
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(n = 2,735 participants) Respondents reported use of various stop smoking medications to 
quit smoking at each survey wave, along with demographic and smoker characteristics. 
The self-reported use of any stop smoking medication has increased significantly over the  
3 year period in all 4 countries, with the sharpest increase occurring in the United States. 
Varenicline has become the second most used stop smoking medication, behind NRT, in 
all  4  countries  since  being  introduced.  Between  2006  and  2008,  varenicline  use  rates 
increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in 
Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained 
constant in each country. Males and non-whites were significantly less likely to report 
using any SSM, while more educated smokers were significantly more likely to use any 
SSM, including varenicline. Our findings suggest that the introduction of varenicline led to 
an increase in the number of smokers who used evidence-based treatment during their quit 
attempts, rather than simply gaining market share at the expense of other medications. 
From  a  public  health  perspective,  messages  regarding  increased  success  rates  among 
medication  users  and  the  relative  safety  of  stop  smoking  medications  should  be 
disseminated widely so as to reach all smokers of all socioeconomic classifications equally. 
Keywords: tobacco cessation; ITC Survey; varenicline 
 
1. Introduction 
Pharmacological  treatments  such  as  nicotine  replacement  therapy  (NRT),  sustained-release 
bupropion, and varenicline are effective in terms of diminishing the severity of withdrawal symptoms 
and reducing the chance of relapse in smokers who make a quit attempt [1-4]. Despite this evidence, 
the majority of smokers today still make their quit attempts without using any form of assistance, 
although the proportion has increased slightly over the past two decades [5]. Approximately 3–5% of 
smokers who make an unaided quit attempt report remaining smoke free one year following their quit 
attempt  [1].  In  the  United  Kingdom,  an  evaluation  of  the  National  Health  Service  (NHS)  Stop 
Smoking  Service  program  indicated  that  smokers  who  attempted  to  quit  using  stop  smoking 
medication and behavioral support provided through the NHS services were nearly 4 times more likely 
to be quit at 52 weeks than smokers who attempted to quit with no assistance [6]. 
Given the number of pharmacotherapies shown to be effective in aiding smoking cessation attempts, 
United States Clinical Practice Guidelines recommend the use of pharmacotherapy for all smokers 
who  want  to  make  a  quit  attempt,  so  as  long  as  no  contraindications  for  medication  use  are  
present [5,7]. In the United Kingdom, the government provides stop smoking medications through the 
National Health Service prescription program [6] and the NHS Stop Smoking Services. In Australia, 
there are no subsidies on the use of NRT, but prescription only medications are subsidized for one 
course of treatment per year, requiring two prescriptions at a small cost to the individual [8]. In Canada, 
stop  smoking  medications  may  be  obtained  on  prescription  or  over  the  counter.  Although  no  
national-level guidelines exist, some Canadian provinces do offer comprehensive subsidy programs for 
smokers who wish to use pharmacotherapy in an attempt to stop smoking [9].  Int. J. Environ. Res. Public Health 2011, 8                 
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Historically,  the  most  common  pharmacotherapy  used  in  smoking  cessation  was  nicotine 
replacement medication, such as the nicotine patch and nicotine gum [10,11]. NRT in the form of gum, 
patch, and lozenge has been available over the counter without a prescription in the United States since 
1996 [12]. The United Kingdom National Health Service has provided NRT on prescription since 
April  2001  [6]  but  NRT  products  are  also  available  over  the  counter  without  a  prescription  in 
pharmacies and in other retail outlets. In Australia, the various forms of NRT became available over 
the counter from pharmacies from 1997 to 2003, with some forms becoming available in ordinary 
stores from 2005, although NRT manufacturers were slow to use this channel, and it still little used [8]. 
In Canada, NRT has been available over the counter without a prescription since 1998 [9].  
Sustained-release bupropion is an atypical antidepressant approved for use in smoking cessation. In 
the United States, bupropion has been approved for use in smoking cessation since 1997. The United 
Kingdom National Health Service has provided bupropion on prescription since June 2000 [6]. It has 
also been available on prescription in Australia since 2000 [8]. Health Canada approved bupropion for 
use via prescription in May 1998 [9].  
Varenicline, a partial agonist of the nicotinic acetylcholine receptor, (Chantix® in the United States 
and  Champix®  in  the  United  Kingdom,  Australia,  and  Canada)  is  a  prescription  stop  smoking 
medication;  clinical  studies  suggest  that  varenicline  has  demonstrated  clinical  efficacy  as  a  stop 
smoking  medication  with  relative  risks  for  quitting  approximately  2.5–3  times  that  of  a  
placebo [13-15]. Varenicline has been available in the United States since August 1, 2006 and in the 
United Kingdom since December 5, 2006 [16]. In Canada, varenicline was has been available since 
April 12, 2007, and since January 1, 2008 in Australia. 
While the clinical studies demonstrate the efficacy of varenicline, few population-based studies that 
examine the prevalence of use of this medication, whether it is displacing users of other stop smoking 
medications,  and  the  characteristics  of  smokers  who  report  the  use  of  medication  as  part  of  a  
quit attempt.  
This study uses data from the International Tobacco Control (ITC) 4 Country Survey to examine 
trends  in  use  of  stop  smoking  medications  between  2006  and  2008  in  the  United  States,  United 
Kingdom,  Australia,  and  Canada,  corresponding  to  the  time  period  when  varenicline  was  made 
available as a government approved stop smoking medication in each of these four countries. The 
overall objective of the study is to examine usage patterns of stop smoking medications in all four 
countries,  with  a  specific  aim  of  examining  how  the  introduction  of  varenicline  into  a  market 
influenced  usage  patterns  for  other  approved  stop  smoking  medications.  Usage  patterns  of  stop 
smoking  medications  are  examined  to  determine  whether  overall  use  has  increased  over  time  or 
whether smokers predisposed to using stop smoking medications have shifted in terms of the type of 
medications they are using. Additionally, characteristics of users of different types of stop smoking 
medications are compared.  
2. Experimental Section 
The data source for this study is the International Tobacco Control (ITC) 4 Country Survey. The 
objective of the International Tobacco Control (ITC) Project is to evaluate effects of national-level and 
sub-national tobacco control policies [17].  Int. J. Environ. Res. Public Health 2011, 8                 
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The ITC Project is a prospective cohort study consisting of surveys in multiple countries. Annual 
surveys of nationally representative samples of smokers have been completed approximately annually 
in  Australia,  Canada,  United  Kingdom,  and  United  States  since  2002.  The  ITC  Survey  asks 
participants questions regarding their smoking behavior, attempts at cessation, and attitudes and beliefs 
about tobacco products, as well as questions pertaining to each of the demand reduction policies of the 
Framework Convention on Tobacco Control (FCTC). Cohort members who are lost to follow-up are 
replaced with newly recruited participants to preserve the overall sample size from wave to wave, thus 
there  is  a  longitudinal  component  to  the  ITC  survey  as  well  as  a  representative  cross-sectional 
component. This study relies on the cross-sectional component of the ITC survey to describe the use of 
stop smoking medications in these four countries.  
For  the  purposes  analyzing  medication  use  patterns,  each  wave  of  data  was  treated  as  an 
independent cross-section. We report data on current smokers (and recent quitters) who reported a quit 
attempt in the year prior to the survey (n = 4,022 in the 2006 wave, n = 3,790 in 2007, and n = 2,735  
in 2008).  
The use of stop smoking medication was calculated based on self-reports. Respondents were asked 
whether they had used any stop smoking medications to quit smoking within the past 12 months and, if 
so, they were read a list of stop smoking medications (including nicotine gum, nicotine patch, nicotine 
lozenge,  nicotine  tablet,  nicotine  inhaler,  nicotine  nasal  spray,  nicotine  water,  bupropion,  and 
varenicline) and asked which they had used each one during this time period.  
The main outcome assessed in each survey was the use of any stop smoking medication to quit 
smoking among participants who reported making a quit attempt in the past year. This included current 
smokers (daily, weekly, or monthly) and recent quitters (quit <1 month, quit 1–6 months, or quit >6 
months).  Respondents  were  asked  whether  they  had  used  any  stop  smoking  medications  to  quit 
smoking within the past 12 months. 
The characteristics of participants who reported using any stop smoking medications at the 2008 
survey were also examined. Variables included in the analysis were sex (male or female), age (18–24, 
25–39,  40–54,  55  and  older),  ethnicity  (majority  group  in  each  country  or  non-majority  group), 
Heaviness of Smoking Index (0, 1, 2, 3, 4, 5, 6—based on a combination of time to first cigarette after 
waking and number of cigarettes smoked per day), income (low, moderate, or high relative to each 
country), and education level (low, moderate, or high relative to each country).  
Data were analyzed using SPSS 15.0 (SPSS Inc., Chicago, IL). Descriptive statistics were used to 
provide estimates of the prevalence of stop smoking medication use to quit smoking at the time of each 
survey. A chi-square test was used to assess trends in use of any stop smoking medication, use of NRT, 
use of bupropion, and use of varenicline between 2006 and 2008. Additionally, three multivariate 
logistic  regression  models  (controlling  for  sex,  age,  ethnicity,  heaviness  of  smoking  index  (HSI), 
income, and education, were constructed in order to examine the characteristics of users of any stop 
smoking medication, NRT, and varenicline users.  
3. Results 
Results from the 2006, 2007, and 2008 ITC 4 country surveys indicate that the self-reported use of 
any stop smoking medication among participants who reported making a quit attempt has steadily Int. J. Environ. Res. Public Health 2011, 8                 
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increased over this three year period in all 4 countries (see Table 1). Between 2006 and 2008, any SSM 
use rates doubled in the United States (24.4% to 48.8%), increased by about 50% in Canada (31.1% to 
45.7%) and Australia (31.5% to 45.6%), and increased by 15% in the UK (31.9% to 36.6%).  
Results indicate that varenicline has become the second most used stop smoking medication, behind 
NRT, in all four countries since being introduced onto each of the four markets. In the US, varenicline 
use in 2008 was comparable to NRT use (21.7% vs. 22.2%, respectively). In Canada and Australia, 
varenicline use went from 0% in 2006 to nearly 15% in 2008. Uptake of varenicline in the UK has 
been  slower  with  rates increasing  from  0%  in  2006  to  4.4%  in  2008.  While  varenicline  use was 
increasing in each country between 2006 and 2008, no statistical differences were observed in NRT or 
bupropion use rates over the same time period in any country.  
Table 1. Use of Stop Smoking Medications 2006, 2007, and 2008. 
   2006  2007  2008 
   N  %  N  %  N  % 
United States   1,025    1,021    658   
  Any SSM    24.4    33.0    48.8 
1 
   NRT    19.5    16.5    22.2 
   Bupropion    4.8    3.4    4.3 
   Varenicline    0.4    13.7    21.7 
1 
United Kingdom  903    843    704   
   Any SSM    31.9    36.3    36.6 
1 
   NRT    29.8    32.7    29.1 
   Bupropion    1.9    1.1    2.0 
   Varenicline    0.0    2.0    4.4
1 
Canada  975    927    676   
   Any SSM    31.1    32.3    45.7 
1 
   NRT    26.8    24.1    24.6 
   Bupropion    4.8    5.5    5.5 
   Varenicline    0.0    2.3    14.8 
1 
Australia  1,119    999    697   
   Any SSM    31.5    35.3    45.6 
1 
   NRT    26.0    29.8    24.5 
   Bupropion    5.2    5.1    5.6 
   Varenicline    0.0    0.1
2    14.5 
1 
1 indicates statistically significant chi-square for trend at the p < 0.001 level 
2 Of 141 respondents interviewed after on market date, 1 participant (0.7%) reported using varenicline 
3.1. Characteristics of Medication Users 
Three multivariate logistic regression models were constructed in order to examine characteristics 
of medication users at the time of the 2008 survey. Results examining the characteristics of SSM users 
are reported on data combined across each country for the 2008 survey. In all of these analyses, the 
denominator was those reporting a quit attempt in the previous year. Data were combined because Int. J. Environ. Res. Public Health 2011, 8                 
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models  examining  interactions  of  variables  included  in  the  model  and  country  did  not  show  any 
differences. These results are presented in Table 2.  
United Kingdom residents were significantly less likely (OR = 0.61; 95%CI: 0.46–0.80) to have 
reported using any SSM relative to the other three countries. Males (OR = 0.73; 95%CI: 0.60–0.89) 
and non-whites (OR = 0.55; 95%CI: 0.38–0.81) were also significantly less likely to have used any 
SSM.  More  educated  smokers  were  more  likely  to  report  using  any  SSM  in  the  year  prior  to  
being surveyed. 
Varenicline  users  were  significantly  more  likely  to  be  United  States  residents  (OR  =  1.53;  
95%CI:  1.06–2.20)  and  significantly  less  likely  to  be  United  Kingdom  residents  (OR  =  0.16;  
95%CI: 0.09–0.30). Males (OR = 0.66; 95%CI: 0.49–0.90) and minority group members (OR = 0.47; 
95%CI: 0.24–0.92) were also significantly less likely to report using varenicline, while more educated 
participants were significantly more likely to report using varenicline. These results are presented in 
Table 2. 
NRT  users  were  significantly  less  likely  to  be  males  (OR  =  0.80;  95%CI:  0.65–0.99).  Older 
smokers (age 25 and up), heavier smokers (as measured by HSI), and more educated smokers were all 
more likely to report using NRT in a quit attempt.  
4. Discussion and Conclusions 
Following its introduction in all four countries, varenicline has become the second-most widely 
used stop smoking medication, although uptake has been slower in the United Kingdom relative to the 
other three countries. Overall stop smoking medication use rates increased among people making quit 
attempts in each country between 2006 and 2008, with approximately 40% reporting the use of stop 
smoking medications in 2008. This increase was driven by sharp increases in varenicline while NRT 
and  bupropion  use  remained  relatively  stable.  Given  the  clinical  trial  evidence  demonstrating  the 
effectiveness of varenicline, our findings suggest that the introduction of varenicline led to an increase 
in the number of smokers who used evidence-based treatment during their quit attempts, rather than 
simply gaining market share at the expense of previously available stop smoking medications.  
The reasons for the difference in the slower rate of uptake in the United Kingdom than in the 
remaining  three  countries  are  unclear.  It’s  possible  that  UK  practitioners  were  more  cautious  to 
prescribe a new smoking cessation drug, or UK smokers more reluctant to request or accept an offer of 
varenicline, because of adverse publicity that had arisen in the UK tabloid press after bupropion was 
launched onto the UK market. This publicity caused a reduction in bupropion use which has remained 
very low ever since [18]. There has also been negative publicity about varenicline (see below). It’s 
unclear why the UK may be differentially affected, although the negative publicity of bupropion was 
covered prominently by its second most popular newspaper. 
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Table 2. Characteristics of stop smoking medication users among quitters from the 2008 ITC 4 Country survey. 
  Users of Any Stop Smoking Medication  Users of Nicotine Replacement Therapy  Users of Varenicline 
  N 
% Used 
Any 
SSM 
OR  Lower CI  Upper CI  N 
% 
Used 
NRT 
OR  Lower CI  Upper CI  N 
% Used 
Varenicline 
OR  Lower CI  Upper CI 
Country                               
Canada  676  45.7  1.00  ref.  676  24.6  1.00  ref.  676  14.8  1.00  ref. 
United States  658  48.8  1.09  0.83  1.44  658  22.2  0.84  0.61  1.15  658  21.7  1.53  1.06  2.20 
United Kingdom  704  36.6  0.61  0.46  0.80  704  29.1  1.18  0.84  1.58  704  4.4  0.16  0.09  0.30 
Australia  697  45.6  0.94  0.72  1.23  697  24.5  0.78  0.72  1.32  697  14.5  0.79  0.53  1.17 
Sex                               
Female  1529  46.6  1.00  ref.  1529  27.1  1.00  ref.  1529  14.7  1.00  ref. 
Male  1206  40.9  0.73  0.60  0.89  1206  22.6  0.80  0.65  0.99  1206  12.4  0.66  0.49  0.90 
Age                               
18-24  140  31.4  1.00  ref.  140  22.1  1.00  ref.  140  4.3  1.00  ref. 
25-39  606  44.4  1.52  0.91  2.52  606  28.2  1.56  0.88  2.76  606  10.9  1.21  0.45  3.27 
40-54  1101  45.1  1.32  0.80  2.15  1101  24.5  1.16  0.66  2.03  1101  15.5  1.67  0.64  4.35 
55 +  888  44.6  1.39  0.84  2.30  888  24.3  1.14  0.64  2.01  888  14.9  1.80  0.68  4.76 
Ethnicity                               
White, English 
Speaking 
2469  45.1  1.00  ref.  2469  25.6  1.00  ref.  2469  14.3  1.00  ref. 
Non-White,  
Non-English 
Speaking 
248  33.5  0.55  0.38  0.81  248  20.2  0.79  0.52  1.21  248  8.1  0.47  0.24  0.92 Int. J. Environ. Res. Public Health 2011, 8                 
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Table 2. Cont. 
  Users of Any Stop Smoking Medication  Users of Nicotine Replacement Therapy  Users of Varenicline 
  N 
% Used 
Any 
SSM 
OR  Lower CI  Upper CI  N 
% 
Used 
NRT 
OR  Lower CI  Upper CI  N 
% Used 
Varenicline 
OR  Lower CI  Upper CI 
Heaviness of 
Smoking Index 
(HSI) 
                             
0  256  35.9  1.00  ref.  256  22.3  1.00  ref.  256  10.9  1.00  ref. 
1  268  38.4  1.19  0.80  1.77  268  23.5  1.14  0.73  1.80  268  10.1  0.95  0.50  1.80 
2  414  46.4  1.92  1.34  2.77  414  30.4  1.78  1.18  2.69  414  12.6  1.35  0.76  2.40 
3  616  43.3  1.64  1.17  2.31  616  23.9  1.36  0.92  2.01  616  13.3  1.33  0.78  2.29 
4  375  44.3  1.56  1.08  2.26  375  24.3  1.27  0.83  1.95  375  13.1  1.36  0.76  2.44 
5  150  48.0  1.84  1.16  2.92  150  29.3  1.69  1.01  2.82  150  14.0  1.25  0.62  2.55 
6  56  42.9  1.51  0.79  2.89  56  28.6  1.59  0.78  3.25  56  7.1  0.55  1.15  1.98 
Income                               
Low  718  46.2  1.00  ref.  718  27.3  1.00  ref.  718  12.1  1.00  ref. 
Moderate  839  42.9  0.83  0.66  1.06  839  24.0  0.82  0.63  1.07  839  13.9  1.18  0.81  1.72 
High  812  44.5  0.96  0.74  1.23  812  25.0  0.78  0.59  1.03  812  14.2  1.46  0.98  2.17 
Education                               
Low  1340  41.9  1.00  ref.  1340  24.3  1.00  ref.  1340  11.6  1.00  ref. 
Moderate  891  46.4  1.31  1.06  1.63  891  25.0  1.10  0.86  1.40  891  15.6  1.56  1.11  2.18 
High  500  45.6  1.32  1.01  1.73  500  27.4  1.26  0.93  1.70  500  16.0  1.60  1.07  2.40 
Note: Bold values indicate statistically significant odds ratios Int. J. Environ. Res. Public Health 2011, 8                 
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The findings in this study of an overall increase in use of stop smoking medications in the UK 
contrasts with the findings of other research which examined trends in SSM prescriptions in the UK 
and  found  no  overall  change  following  the  introduction  of  varenicline,  despite  an  increase  in 
varenicline prescribing [19]. It’s unclear why the two studies have contrasting findings. One possibility 
is that the studies used different methodologies: in this study self report of SSM usage among quit 
attempters is used, wheras in the other UK study [19], medical records of prescriptions issued to all 
patients are considered. Different sources of stop smoking medications are included in the two studies: 
the  ITC  data  include  stop  smoking  medications  purchased  over  the  counter  (OTC)  in  addition  to 
prescriptions. The inclusion of OTC medications in our study may have accounted for the increase in 
SSMs  overall  in  the  UK  and  this  increase  may  partly  be  due  to  the  introduction  of  smokefree 
legislation in the UK in 2007, as such legislation has been shown to increase SSM purchases over the 
counter in other countries [20,21].  
Recent data [22] examining medication use among Australian smokers found similar trends for 
medication use over the same three year time period, but found higher proportions of smokers who 
reported  using  any  stop  smoking  medication  and  NRT.  Differences  in  these  findings  and  those 
reported  in  this  manuscript  could  be  attributable  to  differences  in  sampling  frame  and  
analytic approach.  
Given the research evidence that varenicline is superior to other cessation aids [13-15], some might 
be disappointed that its use has not been greater. It is possible that reports of adverse events among 
varenicline users could be limiting the supply of this drug by some prescribers. A previous report 
indicated  that  adverse  events,  which  can  lead  to  discontinuation,  are  commonly  reported  among 
varenicline  users  [23].  However,  other  data  does  not  suggest  that  serious  adverse  events  with 
varenicline have been experienced beyond what would be expected in a large population of users [24].  
A recently published study found no association between varenicline use and an increased risk of 
depression,  self-harm,  and  suicidal  thoughts  [25].  In  2008,  the  United  States  Food  and  Drug 
Administration issued a public health advisory and subsequently updated varenicline product labeling 
after  reports  surfaced  of  individuals  experiencing  neuropsychiatric  symptoms  including  behavioral 
changes, depressed mood, and suicidal behavior. Similar warnings were released by the European 
Medicines Agency in December 2007 [26]. It is unclear what impact the resulting media attention has 
had on varenicline use rates in the US or in other countries. However, despite these warnings and the 
media attention given to reports of serious adverse events, use of varenicline increased rapidly in the 
2–3 years after its introduction. 
For the most part, all the differences in medication use were largely attributable to differences in 
varenicline use. This suggests that use of varenicline might be subject to different factors than other 
medications. The finding that better educated smokers were more likely to use varenicline might be 
because they were more likely to ask for it as they are aware of its existence and its effectiveness. 
From a public health perspective, messages regarding increased success rates among medication users 
and the relative safety of stop smoking medications should be disseminated widely so as to reach all 
smokers equally.  
One limitation of this study is the relatively small sample size of the number of users of any given 
medication, which limited statistical power for some analyses, and means our statements of no effect, 
should be  read  as  no large effects. We do not attempt to explore possible differences in rates  of Int. J. Environ. Res. Public Health 2011, 8                 
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cessation by medication use because of the complexities of controlling for selection effects would have 
overly complicated this manuscript. Cessation rates for different SSM users will be reported as future 
waves of ITC data are collected.  
Based on the currently available data, we find that varenicline use increased quickly in the US, 
Canada, and Australia with slower increases in the UK. Trends in the use of NRT and bupropion were 
relatively stable in all four countries during the period of time between 2006 and 2008. This suggests 
that the bulk of varenicline use comes from those who would not otherwise be using medications. We 
do not know whether this is because this group have used other medications previously and failed with 
them or they are a new group who had been reluctant to use what had been available. It is important to 
continue to monitor trends in the use of stop smoking medications, including varenicline.  
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